Is Olaparib chemotherapy or a targeted drug?

Olaparib is a targeted drug that is used in many cancers. Patients can take it alone, in combination with another anticancer drug (such as bevacizumab), or as part of a clinical trial. Olaparib is a targeted drug called PARP inhibitor. PARP is a protein that helps damaged cells repair themselves. OlaparibwillstopPARP work. Some cancer cells rely on PARP to keep their DNA healthy. This includes cancer cells with changes in the BRCA gene.

When olaparib blocksPARP from repairing DNA damage, cancer cells die. Lynparza is suitable for people who have changes in their BRCA1 or BRCA2 genes. Not everyone can test for these gene changes before taking Lynparza. For prostate cancer, if the cancer comes back while you're on hormone therapy, you have it. Doctors also use olaparib as maintenance treatment after chemotherapy in patients whose cancer has returned and responded well to platinum-based chemotherapy drugs. Maintenance treatment is designed to keep the cancer from coming back or growing for as long as possible. This may not be suitable for everyone.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.